Cadila Healthcare bags USFDA's approval for marketing of Tizanidine
DSIJ Intelligence / 08 Mar 2017
Cadila Healthcare has announced the attainment of USFDA's final approval for the marketing of Tizanidine Hydrochloride capsules.
Cadila Healthcare has announced the attainment of USFDA's final approval for the marketing of Tizanidine Hydrochloride capsules, post recieving observations from USFDA under Form 483 for its formulations manufacturing facility located at its SEZ in Baddi, Gujarat.
USFDA, the United States Food and Drug Adminstration, is the USA's federal agency for health and human services. While, Zydus Cadila (now called Cadila Healthcare), based in Gujarat, is one of the leading pharmaceutical firms worth Rs 54.7 billion.
Cadila Healthcare is trading at Rs 439, with a 0.73 per cent hike in its stocks.
The stocks had witnessed its 52-week high in February 2017 at Rs 460.
However, with USFDA's appoval for Tizanidine Hydrochloride, which is a short-acting, muscle relaxer drug, the stocks are expected to further rise.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.